Tag: cellular immunotherapy market forecast

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Cellular Immunotherapy Market Size And Revenue Outlook Through 2030

The cellular immunotherapy market has shown rapid expansion recently. It is anticipated to increase from $6.56 billion in 2025 to $7.48 billion in 2026, with a compound annual growth rate (CAGR) of 14.1%. The market’s past growth is attributable to the success of early car-t therapies, unmet oncology needs, growth in research funding, regulatory approvals, and academic-industry collaboration.

The cellular immunotherapy market is projected to experience substantial expansion in the coming years, reaching $12.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.7%. This growth during the forecast period is primarily driven by factors such as the expansion of therapies into solid tumors, advancements in NK cell therapy, the development of scalable manufacturing processes, favorable regulatory environments, and increased financial commitment to oncology. Key trends anticipated for this period involve the swift rise of CAR-T cell therapies, the broadening application of allogeneic cell therapies, their increased utilization in treating hematologic malignancies, breakthroughs in T cell engineering, and a surge in clinical trial engagements.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=19960853&type=smp&name=Cellular%20Immunotherapy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cellular Immunotherapy Market Growth Factors Behind Sustained Expansion

The expansion of the cellular immunotherapy market is anticipated to be fueled by the increasing occurrence of cancer. Cancer is defined as a cluster of diseases characterized by the unrestrained proliferation and dissemination of abnormal cells throughout the body. The uptick in cancer prevalence is largely attributed to an aging global population, various lifestyle choices, and enhancements in diagnostic and screening protocols. Moreover, environmental exposures and genetic predispositions contribute significantly to the rising incidence rates. Cellular immunotherapy operates by strengthening the immune system’s response against cancer through the targeted destruction of tumor cells, consequently improving patient survival rates. This therapeutic strategy, when integrated with other treatments, holds the promise of decreasing both new cancer cases and their recurrence. For instance, in March 2024, MAC Clinical Research, a UK-based cancer research organization, reported that the estimated number of people living with cancer in the United Kingdom is expected to climb from around 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the escalating prevalence of cancer is undeniably propelling the growth within the cellular immunotherapy market.

Cellular Immunotherapy Market Segment Analysis And Revenue Potential

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

Cellular Immunotherapy Market Industry Trends Fueling Future Revenue Growth

Leading companies in the cellular immunotherapy market are focused on developing technological advancements, such as immunotherapy, to enhance treatment efficacy and expand their applications. Their efforts are directed towards personalized medicine, combination therapies, and scalable manufacturing to improve patient outcomes. Immunotherapy itself is a medical approach that utilizes the body’s immune system to fight diseases, especially cancer. This can involve boosting natural immune responses or delivering targeted therapies to strengthen immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, highlighted CAR-T cell therapy. This revolutionary cancer treatment uses genetically engineered T cells to specifically target and destroy cancer cells, providing a personalized approach. It offers durable remission rates, particularly for resistant blood cancers, while minimizing damage to healthy tissues.

Cellular Immunotherapy Market Key Players Shaping Industry Direction

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

View The Full Cellular Immunotherapy Market Report:

https://thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cellular Immunotherapy Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cellular Immunotherapy Market Size Outlook: How Fast Will Revenue Grow Through 2030?

In recent times, the market for cellular immunotherapy has expanded significantly. From a valuation of $6.56 billion in 2025, it is projected to reach $7.48 billion by 2026, reflecting a compound annual growth rate of 14.1%. The expansion observed in the historical period was driven by several key factors, including the achievements of initial CAR-T therapies, the existence of unaddressed requirements in oncology, an increase in research funding, the granting of regulatory approvals, and cooperative efforts between academia and industry.

The cellular immunotherapy market is anticipated to undergo rapid expansion over the coming years. By 2030, its valuation is projected to reach $12.5 billion, driven by a compound annual growth rate (CAGR) of 13.7%. This forecasted growth is largely fueled by advancements in solid tumor treatment, breakthroughs in NK cell therapy, the development of scalable manufacturing processes, the establishment of supportive regulatory environments, and heightened levels of oncology funding. Key trends shaping this period include the swift expansion of CAR-T cell therapies, the growing adoption of allogeneic cell treatments, an increased application in hematologic malignancies, notable progress in T cell engineering, and a surge in clinical trial activity.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cellular Immunotherapy Market Industry Drivers: What Is Driving Revenue Growth?

The growing incidence of cancer is anticipated to drive expansion in the cellular immunotherapy market moving forward. Cancer encompasses a range of diseases marked by the abnormal, uncontrolled growth and dissemination of cells within the body. This upward trend in cancer prevalence can be attributed primarily to an aging demographic, lifestyle-related choices, and enhancements in screening and detection methods. Additionally, environmental factors and hereditary susceptibilities contribute significantly to higher occurrence rates. Cellular therapy strengthens the body’s immune defense against tumors by directly targeting malignant cells, thereby enhancing patient survival outcomes. When integrated with other therapeutic modalities, this strategy has the potential to lower both cancer incidence and recurrence rates. As an illustration, data from March 2024, released by MAC Clinical Research—a UK-based cancer research entity—shows that the number of individuals living with cancer in the United Kingdom is projected to climb from roughly 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer is fueling the growth of the cellular immunotherapy sector.

Cellular Immunotherapy Market Categorization By Product Type And Application

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

Cellular Immunotherapy Market Growth Trends: What Is Influencing The Future Outlook?

Key industry players in the cellular immunotherapy market are prioritizing innovations like immunotherapy to improve treatment effectiveness and broaden its use. Their efforts center on personalized medicine, combination therapies, and scalable manufacturing processes to enhance patient outcomes. Immunotherapy leverages the body’s own immune system to combat diseases, particularly cancer, by either amplifying immune responses or deploying targeted therapies that boost immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, a healthcare provider based in India, adopted CAR-T cell therapy—a groundbreaking cancer treatment that uses genetically modified T cells to precisely identify and destroy cancer cells. This personalized method achieves durable remission, especially for resistant blood cancers, while reducing harm to healthy tissues.

Cellular Immunotherapy Market Company Landscape And Strategic Competition

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Cellular Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cellular Immunotherapy Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Cellular Immunotherapy Market Compare Between 2026 And 2030?

The cellular immunotherapy market has experienced rapid growth in its size in recent years. It is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been attributed to the achievements of early CAR-T therapies, the existence of unmet oncology needs, increased research funding, regulatory approvals, and collaborations between academic institutions and industry.

The cellular immunotherapy market is set for significant expansion over the next few years. It is forecasted to achieve a valuation of $12.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.7%. This anticipated growth can be attributed to several factors including its expansion into solid tumors, continued innovation in nk cell therapy, the adoption of scalable manufacturing technologies, supportive regulatory frameworks, and increased oncology investment. Key trends expected during this period involve the rapid growth of car-t cell therapies, the broader application of allogeneic cell therapies, a rising use in hematologic malignancies, advancements in t cell engineering, and heightened clinical trial activity.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Are The Main Drivers Accelerating The Growth Of The Cellular Immunotherapy Market?

The increasing incidence of cancer is anticipated to fuel the expansion of the cellular immunotherapy market moving forward. Cancer refers to a collection of diseases marked by the uncontrolled multiplication and spread of abnormal cells throughout the body. The growing prevalence of cancer is largely a result of an aging population, lifestyle choices, and enhanced screening and diagnostic capabilities. Environmental exposures and genetic predispositions also play crucial roles in elevating incidence rates. Cellular immunotherapy boosts the immune system’s response against cancer by precisely targeting tumor cells, leading to improved survival rates. This technique, when combined with other therapies, could contribute to a reduction in cancer incidence and recurrence. For instance, in March 2024, according to MAC Clinical Research, a UK-based cancer research organization, the estimated number of individuals living with cancer in the United Kingdom is projected to rise from approximately 3 million at present to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the escalating prevalence of cancer is a key driver for the growth of the cellular immunotherapy market.

How Is Segment Classification Applied In The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

What Trends Are Impacting The Cellular Immunotherapy Market?

Leading entities within the cellular immunotherapy sector are concentrating on advancing technologies, notably immunotherapy itself, aiming to improve treatment effectiveness and broaden its utility. Key areas of their attention encompass personalized medical approaches, combined therapeutic strategies, and manufacturing processes that can be scaled, all designed to achieve superior patient results. Immunotherapy functions as a therapeutic method leveraging the body’s own immune system to combat illnesses, particularly cancer; this involves either stimulating immune responses or administering specific treatments to amplify immune action against particular cells. As an illustration, in December 2023, Max Healthcare Institute Limited operates as an India-based healthcare service provider company. CAR-T cell therapy represents a groundbreaking cancer treatment, employing genetically modified T cells to precisely identify and eliminate cancer cells, thereby providing a customized strategy. This therapy delivers lasting remission rates, especially for blood cancers that are resistant to other treatments, concurrently reducing harm to healthy body tissues.

Which Industry Players Are Present In The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Cellular Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Has The Strongest Presence In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cellular Immunotherapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Cellular Immunotherapy Market In 2026, And How Will Its Value Evolve By 2030?

The cellular immunotherapy market has experienced substantial expansion recently. This market is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been driven by factors such as the achievements of initial CAR-T therapies, addressing unmet needs in oncology, an increase in research funding, obtaining regulatory approvals, and strong academic-industry partnerships.

The cellular immunotherapy market is anticipated to undergo significant expansion in the foreseeable future. Its valuation is predicted to ascend to $12.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.7%. This growth during the projection period stems from its extension into solid tumors, breakthroughs in nk cell therapy, the emergence of scalable manufacturing technologies, supportive regulatory frameworks, and augmented investment in oncology. Prominent developments expected throughout this period include the rapid proliferation of car-t cell therapies, the broadening scope of allogeneic cell therapies, their increased application in hematologic malignancies, continuous advancements in t cell engineering, and a surge in clinical trial engagements.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Drivers Are Supporting The Cellular Immunotherapy Market Growth?

The expanding incidence of cancer is expected to drive the growth of the cellular immunotherapy market going forward. Cancer is defined as a group of diseases characterized by the uncontrolled multiplication and spread of abnormal cells within the body. This rising prevalence is largely due to an aging population, various lifestyle factors, and improved screening and diagnosis techniques. Environmental exposures and genetic predispositions also play considerable roles in increasing the incidence rates. Cellular immunotherapy operates by enhancing the immune system’s response to specifically target tumor cells, which improves survival rates. This strategy, when combined with other treatments, has the potential to reduce both cancer incidence and recurrence. As an illustration, in March 2024, MAC Clinical Research, a UK-based cancer research organization, estimated that the number of individuals living with cancer in the United Kingdom is set to increase from approximately 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the increasing prevalence of cancer is a primary catalyst for the cellular immunotherapy market’s expansion.

What Are The Main Segments Within The Cellular Immunotherapy Market Segment Structure?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

Which Trends Are Guiding The Direction Of The Cellular Immunotherapy Market?

Leading companies in the cellular immunotherapy market are concentrating on developing technological advancements, such as immunotherapy itself, to enhance treatment efficacy and broaden applications. Their efforts are directed towards personalized medicine, combination therapies, and scalable manufacturing processes to improve patient outcomes. Immunotherapy involves a medical strategy that utilizes the body’s inherent immune system to combat diseases, especially cancer. This approach can either bolster immune responses or administer targeted therapies to heighten immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider company, was active in this domain. CAR-T cell therapy is recognized as a revolutionary cancer treatment, utilizing genetically engineered T cells to precisely target and eliminate cancer cells, thus offering a personalized methodology. It offers durable remission rates, particularly for resistant blood cancers, while concurrently minimizing harm to healthy tissues.

Who Are The Companies Participating In The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Get The Full Cellular Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Is The Leading Market For The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cellular Immunotherapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Cellular Immunotherapy Market In 2026 And What Value Is Projected For 2030?

The cellular immunotherapy market has demonstrated rapid expansion in its size over recent years. It is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. Historically, this growth has been fueled by the achievements of early CAR-T therapies, persistent unmet needs in oncology, an increase in research funding, timely regulatory approvals, and strong academic-industry collaboration.

The cellular immunotherapy market is poised for significant expansion in the coming years. It is projected to achieve a valuation of $12.5 billion by 2030, growing at a robust compound annual growth rate (CAGR) of 13.7%. This anticipated growth during the forecast period stems from factors such as the expansion into solid tumors, innovations in NK cell therapy, advancements in scalable manufacturing technologies, supportive regulatory frameworks, and increased investment in oncology. Prominent trends observed within this period include the rapid growth of CAR-T cell therapies, the broadening application of allogeneic cell therapies, their escalating utilization in hematologic malignancies, continuous advancements in T cell engineering, and a notable rise in clinical trial activity.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Cellular Immunotherapy Market?

The increasing incidence of cancer is projected to drive the expansion of the cellular immunotherapy market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. This growing prevalence is primarily attributed to an aging demographic, various lifestyle elements, and advancements in screening and diagnostic methods. Furthermore, environmental influences and genetic susceptibilities contribute substantially to the escalating incidence figures. Cellular immunotherapy enhances the body’s immune reaction against cancer through precise targeting of tumor cells, thereby elevating survival prospects. When combined with other therapeutic interventions, this method holds the potential to reduce both the occurrence and reoccurrence of cancer. For example, data from March 2024, provided by MAC Clinical Research, a cancer research organization based in the UK, indicates that the projected number of individuals living with cancer in the United Kingdom is anticipated to rise from approximately 3 million presently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the expanding incidence of cancer is stimulating the development of the cellular immunotherapy market.

What Are The Key Segments Of The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

What Key Trends Are Influencing The Development Of The Cellular Immunotherapy Market?

Leading companies within the cellular immunotherapy sector are prioritizing technological progress, such as immunotherapy, with the goal of improving treatment effectiveness and broadening its applications. Their strategic emphasis includes personalized medical approaches, combination therapies, and scalable manufacturing processes designed to enhance patient outcomes. Immunotherapy is a medical intervention that utilizes the body’s own immune system to combat diseases, particularly cancer. This can involve either stimulating immune responses or administering targeted therapies to amplify immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, recognized CAR-T cell therapy as a groundbreaking cancer treatment. This therapy employs genetically engineered T cells to precisely target and eradicate cancer cells, thereby offering a tailored treatment method. It yields sustained remission rates, especially for refractory blood cancers, while simultaneously reducing harm to healthy tissues.

Who Are The Leading Companies Operating In The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Read the full cellular immunotherapy market report here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Are The Leading Geographic Regions In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cellular Immunotherapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cellular immunotherapy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Cellular Immunotherapy Market?

The cellular immunotherapy market size has experienced rapid expansion in recent years. This market is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, the growth in this sector has been driven by the success of early CAR-T therapies, the prevalent unmet oncology needs, an increase in research funding, favorable regulatory approvals, and robust academic-industry collaboration.

The cellular immunotherapy market is projected to experience substantial expansion in the coming years. Its valuation is predicted to reach $12.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.7%. This projected growth during the forecast period is attributable to several factors, including the expansion into solid tumors, innovation in nk cell therapy, scalable manufacturing technologies, supportive regulatory frameworks, and increased oncology investment. Significant trends expected over the forecast period encompass the rapid growth of car-t cell therapies, the expansion of allogeneic cell therapies, increasing use in hematologic malignancies, advancements in t cell engineering, and rising clinical trial activity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Drivers Are Supporting The Rise Of The Cellular Immunotherapy Market?

The expanding occurrence of cancer is projected to stimulate the advancement of the cellular immunotherapy market in the future. Cancer constitutes a category of illnesses marked by the uncontrolled multiplication and dissemination of atypical cells within the body. The increasing incidence of cancer primarily stems from an aging demographic, various lifestyle influences, and enhancements in screening and diagnostic methods. Additionally, environmental exposures and genetic susceptibilities contribute substantially to the escalating rates of new cases. Cellular immunotherapy enhances the immune system’s fight against cancer by precisely targeting cancerous cells, thereby improving patient survival outcomes. When combined with other therapeutic interventions, this method has the potential to reduce both the occurrence and re-emergence of cancer. For example, data from March 2024, provided by MAC Clinical Research, a cancer research entity based in the UK, indicates that the projected count of individuals living with cancer in the United Kingdom will climb from approximately 3 million at present to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the expanding occurrence of cancer is fueling the expansion of the cellular immunotherapy market.

What Segments Are Identified Within The Structure Of The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

Which Trends Are Shaping Activity Within The Cellular Immunotherapy Market?

Key companies active in the cellular immunotherapy market are prioritizing the creation of technological advancements like immunotherapy. This effort aims to improve treatment efficacy and broaden their applications. Their strategic areas include personalized medicine, combination therapies, and scalable manufacturing processes to enhance patient outcomes. Immunotherapy is a medical strategy that utilizes the body’s immune system to combat diseases, particularly cancer. It can involve stimulating immune responses or delivering targeted treatments to bolster immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider company, was highlighted. CAR-T cell therapy stands as a groundbreaking cancer treatment that uses genetically altered T cells to specifically target and eliminate cancer cells, offering a tailored approach. It yields sustained remission rates, especially for resistant blood cancers, while limiting damage to healthy tissues.

Which Key Market Players Are Investing In Expansion And Innovation Within The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Regions Are Poised For Strategic Growth In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cellular Immunotherapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the wellness supplements market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Wellness Supplements Market Size?

The cellular immunotherapy market has shown rapid expansion in its size over recent years. It is anticipated to increase from $5.72 billion in 2024 to $6.56 billion in 2025, with a compound annual growth rate (CAGR) of 14.7%. Historical growth in this sector can be attributed to advancements in cancer treatment, successful clinical outcomes, regulatory approvals, and the rising incidence of targeted diseases.

The cellular immunotherapy market is projected for significant expansion in the coming years, anticipated to reach “$11.03 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 13.9%. Factors contributing to this growth during the forecast period include the expansion into solid tumors, enhancements in manufacturing processes, robust healthcare infrastructure, and increased research funding. Key trends expected within this period encompass significant investments in research and development, emerging clinical trial data, and the rise of combination therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Core Market Drivers Are Expanding The Wellness Supplements Industry?

The cellular immunotherapy market is expected to expand over the forecast period, driven by increasing research and successful clinical trials in cellular immunotherapy. Companies are focusing on developing new cellular immunotherapies for treating different diseases. For instance, in June 2022, a report published by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers, indicated that as of April 2022, the worldwide immuno-oncology pipeline contained 2,756 active cell therapy drugs. This figure represents an increase of 36% from the 2021 landscape analysis, which had revealed 2,031 such agents, though it also marked a slight slowdown from the 43% growth recorded in the previous year. The rapid growth observed in the development of cellular immunotherapy at clinical and preclinical stages in 2020, when compared to 2019, is projected to expand the overall landscape of cellular immunotherapy. Subsequently, this expansion is expected to generate higher revenues for the growth of the cellular immunotherapy market.

What Segment Insights Are Highlighted In The Wellness Supplements Market Report?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Which Notable Trends Are Transforming The Wellness Supplements Market Outlook?

Companies within the cellular immunotherapy market are prioritizing the creation of off-the-shelf allogeneic therapies for advanced and innovative cancer treatment. These off-the-shelf allogeneic therapies are derived from donor cells, in contrast to autologous therapy which utilizes a patient’s own cells. Their standardized nature offers advantages such as economic efficiency, large-scale production, rapid manufacturing, and robust quality control. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company dedicated to drug discovery, development, manufacturing, and commercialization, announced that the US Food and Drug Administration (FDA) granted expedited approval for Kymriah (tisagenlecleucel) to treat adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) following two or more lines of systemic therapy. Additionally, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial in August 2020 to evaluate ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors.

Which Firms Are Driving Innovation Within The Wellness Supplements Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Regional Trends Are Shaping Growth In The Wellness Supplements Market?

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

Browse Through More Reports Similar to the Global Wellness Supplements Market 2025, By The Business Research Company

Drugs For Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Colorectal Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model